Cargando…

Global metabolomic profiling of uterine leiomyomas

BACKGROUND: Uterine leiomyomas can be classified into molecularly distinct subtypes according to their genetic triggers: MED12 mutations, HMGA2 upregulation, or inactivation of FH. The aim of this study was to identify metabolites and metabolic pathways that are dysregulated in different subtypes of...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinonen, Hanna-Riikka, Mehine, Miika, Mäkinen, Netta, Pasanen, Annukka, Pitkänen, Esa, Karhu, Auli, Sarvilinna, Nanna S, Sjöberg, Jari, Heikinheimo, Oskari, Bützow, Ralf, Aaltonen, Lauri A, Kaasinen, Eevi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729474/
https://www.ncbi.nlm.nih.gov/pubmed/29073636
http://dx.doi.org/10.1038/bjc.2017.361
_version_ 1783286204533309440
author Heinonen, Hanna-Riikka
Mehine, Miika
Mäkinen, Netta
Pasanen, Annukka
Pitkänen, Esa
Karhu, Auli
Sarvilinna, Nanna S
Sjöberg, Jari
Heikinheimo, Oskari
Bützow, Ralf
Aaltonen, Lauri A
Kaasinen, Eevi
author_facet Heinonen, Hanna-Riikka
Mehine, Miika
Mäkinen, Netta
Pasanen, Annukka
Pitkänen, Esa
Karhu, Auli
Sarvilinna, Nanna S
Sjöberg, Jari
Heikinheimo, Oskari
Bützow, Ralf
Aaltonen, Lauri A
Kaasinen, Eevi
author_sort Heinonen, Hanna-Riikka
collection PubMed
description BACKGROUND: Uterine leiomyomas can be classified into molecularly distinct subtypes according to their genetic triggers: MED12 mutations, HMGA2 upregulation, or inactivation of FH. The aim of this study was to identify metabolites and metabolic pathways that are dysregulated in different subtypes of leiomyomas. METHODS: We performed global metabolomic profiling of 25 uterine leiomyomas and 17 corresponding myometrium specimens using liquid chromatography–tandem mass spectroscopy. RESULTS: A total of 641 metabolites were detected. All leiomyomas displayed reduced homocarnosine and haeme metabolite levels. We identified a clearly distinct metabolomic profile for leiomyomas of the FH subtype, characterised by metabolic alterations in the tricarboxylic acid cycle and pentose phosphate pathways, and increased levels of multiple lipids and amino acids. Several metabolites were uniquely elevated in leiomyomas of the FH subtype, including N6-succinyladenosine and argininosuccinate, serving as potential biomarkers for FH deficiency. In contrast, leiomyomas of the MED12 subtype displayed reduced levels of vitamin A, multiple membrane lipids and amino acids, and dysregulation of vitamin C metabolism, a finding which was also compatible with gene expression data. CONCLUSIONS: The study reveals the metabolomic heterogeneity of leiomyomas and provides the requisite framework for strategies designed to target metabolic alterations promoting the growth of these prevalent tumours.
format Online
Article
Text
id pubmed-5729474
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-57294742018-12-05 Global metabolomic profiling of uterine leiomyomas Heinonen, Hanna-Riikka Mehine, Miika Mäkinen, Netta Pasanen, Annukka Pitkänen, Esa Karhu, Auli Sarvilinna, Nanna S Sjöberg, Jari Heikinheimo, Oskari Bützow, Ralf Aaltonen, Lauri A Kaasinen, Eevi Br J Cancer Genetics & Genomics BACKGROUND: Uterine leiomyomas can be classified into molecularly distinct subtypes according to their genetic triggers: MED12 mutations, HMGA2 upregulation, or inactivation of FH. The aim of this study was to identify metabolites and metabolic pathways that are dysregulated in different subtypes of leiomyomas. METHODS: We performed global metabolomic profiling of 25 uterine leiomyomas and 17 corresponding myometrium specimens using liquid chromatography–tandem mass spectroscopy. RESULTS: A total of 641 metabolites were detected. All leiomyomas displayed reduced homocarnosine and haeme metabolite levels. We identified a clearly distinct metabolomic profile for leiomyomas of the FH subtype, characterised by metabolic alterations in the tricarboxylic acid cycle and pentose phosphate pathways, and increased levels of multiple lipids and amino acids. Several metabolites were uniquely elevated in leiomyomas of the FH subtype, including N6-succinyladenosine and argininosuccinate, serving as potential biomarkers for FH deficiency. In contrast, leiomyomas of the MED12 subtype displayed reduced levels of vitamin A, multiple membrane lipids and amino acids, and dysregulation of vitamin C metabolism, a finding which was also compatible with gene expression data. CONCLUSIONS: The study reveals the metabolomic heterogeneity of leiomyomas and provides the requisite framework for strategies designed to target metabolic alterations promoting the growth of these prevalent tumours. Nature Publishing Group 2017-12-05 2017-10-26 /pmc/articles/PMC5729474/ /pubmed/29073636 http://dx.doi.org/10.1038/bjc.2017.361 Text en Copyright © 2017 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Genetics & Genomics
Heinonen, Hanna-Riikka
Mehine, Miika
Mäkinen, Netta
Pasanen, Annukka
Pitkänen, Esa
Karhu, Auli
Sarvilinna, Nanna S
Sjöberg, Jari
Heikinheimo, Oskari
Bützow, Ralf
Aaltonen, Lauri A
Kaasinen, Eevi
Global metabolomic profiling of uterine leiomyomas
title Global metabolomic profiling of uterine leiomyomas
title_full Global metabolomic profiling of uterine leiomyomas
title_fullStr Global metabolomic profiling of uterine leiomyomas
title_full_unstemmed Global metabolomic profiling of uterine leiomyomas
title_short Global metabolomic profiling of uterine leiomyomas
title_sort global metabolomic profiling of uterine leiomyomas
topic Genetics & Genomics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729474/
https://www.ncbi.nlm.nih.gov/pubmed/29073636
http://dx.doi.org/10.1038/bjc.2017.361
work_keys_str_mv AT heinonenhannariikka globalmetabolomicprofilingofuterineleiomyomas
AT mehinemiika globalmetabolomicprofilingofuterineleiomyomas
AT makinennetta globalmetabolomicprofilingofuterineleiomyomas
AT pasanenannukka globalmetabolomicprofilingofuterineleiomyomas
AT pitkanenesa globalmetabolomicprofilingofuterineleiomyomas
AT karhuauli globalmetabolomicprofilingofuterineleiomyomas
AT sarvilinnanannas globalmetabolomicprofilingofuterineleiomyomas
AT sjobergjari globalmetabolomicprofilingofuterineleiomyomas
AT heikinheimooskari globalmetabolomicprofilingofuterineleiomyomas
AT butzowralf globalmetabolomicprofilingofuterineleiomyomas
AT aaltonenlauria globalmetabolomicprofilingofuterineleiomyomas
AT kaasineneevi globalmetabolomicprofilingofuterineleiomyomas